Navigation Links
AHRQ Expands Therapeutics Education and Research Centers and Adds New Topics: Health IT, Economics, Formularies
Date:10/12/2007

ROCKVILLE, Md., Oct. 12 /PRNewswire-USNewswire/ -- The Agency for Healthcare Research and Quality, part of the U.S. Department of Health and Human Services, announced today the award of $41.6 million over the next 4 years for a new coordinating center and 10 research centers as part of its Centers for Education and Research on Therapeutics program. Four new centers are also added to the CERTs program.

"Expanding the Centers for Education and Research on Therapeutics Program allows AHRQ to build a strong evidence base that consumers, clinicians, and others can use to make critical treatment decisions about therapeutic products and interventions," said AHRQ Director Carolyn M. Clancy, M.D. "The increased number and breadth of expertise in the CERTs will broaden the range of knowledge to help the health care system make measurable improvements in the quality and safety of medications and other treatments and health care."

The new AHRQ-funded CERTs Coordinating Center is Kaiser Permanente's Center for Health Research in Portland, Ore. In addition to assuming infrastructure and leadership support for the CERTs National Steering Committee and research centers, the Center for Health Research will expand the program's ability to translate research findings through collaborations with other research networks, including the National Institutes of Health Roadmap's Clinical Trials Initiative, the NIH Clinical and Translational Science Awards, and AHRQ's Effective Healthcare Program.

In addition to the new coordinating center, there are now 14 CERTs program centers in all. The four new centers receiving first-time funding are:

-- Brigham and Women's Hospital in Boston, which will focus is how health

information technology can improve the safe use of medications

-- The University of Illinois at Chicago, which will focus is how

reinvigorating formularies promote best medication uses

-- Cincinnati's Children's Hospital Me
'/>"/>

SOURCE Agency for Healthcare Research and Quality
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. The Cleveland Clinic Expands Its Services across the World via the Net
2. Ranbaxy Expands By Acquiring A Generic Company In Belgium
3. Insulin and Growth Hormone, Expands Life Span?
4. Health Insurance Company Expands Product Range
5. Bird Flu Outbreak Expands in Vietnam
6. VBI Provides Potential Targets to Diabetes Therapeutics
7. CELL THERAPEUTICS PAYS Heavily to Resolve Dispute FOR ALLEGED ILLEGAL MARKETING OF CANCER DRUG
8. Paracetamol May Cause Live Damage Warns Consumer Education and Research Centre
9. Education Levels Found To Predict Stress
10. Education in women brings sounder sleep
11. Education And Income Level May Not Guarantee Health

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)...LLAS, Nov. 5 Kimberly-Cl...expiration of the waiting period under the Hart-Sc... to its previously announced planned acquisition o...y-Clark initiated a cash tender offer on October 2...ow common stock. The tender offer will expire at ...
(Date:11/5/2009)...light elevation was linked to coronary artery calc...(HealthDay News) -- Elevated blood levels of phosp...isease, U.S. researchers say. , They studied th...ry calcification (CAC) in nearly 900 healthy adult...ation of heart disease risk factors. CAC is an ear...
(Date:11/5/2009)... Lumenis® Ltd. a global devel...sed and radiofrequency devices for ophthalmic, sur...the initiation of a clinical study into the effica...acular Edema (DME). The study will take place at t...adership of Prof. Anat Loewenstein MD. , ...
(Date:11/5/2009)...N DIEGO, Nov. 5 Cadence ...aceutical company focused on in-licensing, develop...ates principally for use in the hospital setting, ... nine months ended September 30, 2009. ,, Based...he FDA for Cadence,s New Drug Application (NDA) fo...
(Date:11/5/2009)... could aid understanding of human diseases, scient... News) -- The genome of the domestic horse has bee...he breeding of horses and may help studies of huma...searchers. , "Having access to multiple genome ...s, including our own. By looking at the horse geno...
Breaking Medicine News(10 mins):Health News:Kimberly-Clark Corporation Announces Regulatory Clearance for Its Planned Acquisition of I-Flow Corporation 2Health News:Kimberly-Clark Corporation Announces Regulatory Clearance for Its Planned Acquisition of I-Flow Corporation 3Health News:Kimberly-Clark Corporation Announces Regulatory Clearance for Its Planned Acquisition of I-Flow Corporation 4Health News:Phosphorus Levels May Predict Heart Disease 2Health News:Lumenis Announces the Initiation of a Clinical Study into the Efficacy of Selective Retina Therapy (SRT) in Diabetic Macular Edema (DME) 2Health News:Lumenis Announces the Initiation of a Clinical Study into the Efficacy of Selective Retina Therapy (SRT) in Diabetic Macular Edema (DME) 3Health News:Lumenis Announces the Initiation of a Clinical Study into the Efficacy of Selective Retina Therapy (SRT) in Diabetic Macular Edema (DME) 4Health News:Lumenis Announces the Initiation of a Clinical Study into the Efficacy of Selective Retina Therapy (SRT) in Diabetic Macular Edema (DME) 5Health News:Lumenis Announces the Initiation of a Clinical Study into the Efficacy of Selective Retina Therapy (SRT) in Diabetic Macular Edema (DME) 6Health News:Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results 2Health News:Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results 3Health News:Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results 4Health News:Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results 5Health News:Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results 6Health News:Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results 7Health News:Complete Horse Genome Sequence Revealed 2
...t disease, cancer, and stroke, three leading kille...n 2 percent to 5 percent.// Also, Americans'...77.3 the year before. By comparison, it was 75.4 i...ne and sanitation, and declines in unhealthy habit...
...roduced by Pharmaceutical companies which are prov...ilable in Africa, where the actual benefit of thes... Frontiers (Doctors Without Border). MSF (Medicin...er 57,000 people in 29 countries. MSF has accu...
...nfection has caused the death of a 5 year old boy ...a. The boy is not found to be in direct contact wi...d have contacted the virus from the neighboring po...on to manufacturers to produce generic version of ...
...tch-22 situation for some overweight people—they c...tinal problems//. Doctors treating overweight...t of a regime to take off pounds. But rese...f gastrointestinal problems that frequently affect...
... breast cancer should not be a stimulation to be r...econdary infection//. This arises due to its t...nvironmental risks compared with the general popul...ancer, soft tissue sarcoma, endometrial cancer, me...
...aver, a professor of neurology at the University o...nt lines of research on stroke has highlighted tha...just a second following an acute episode of stroke... minute following the attack. He has been co...
Other Medicine News:Health News:US life expectancy climbs to a new high 2Health News:Stroke Destroys Nearly 32, 000 Neurons In Just A Second! 2
(Date:11/5/2009)..., BOTHELL, Wash., Nov. 5 /PRNewswire-FirstCall/... ), a global leader in automated external defibril...devices, announced today it appointed veteran heal...ard of directors. Andrews replaces long-time board...rom his board seat effective November 5th. The tot...
(Date:11/5/2009)..., BRISBANE, Calif., Nov. 5 /PRNewswire-FirstCal...nced results from operations for the third quarter...rMune reported a net loss for the third quarter of...d with a net loss of $14.0 million, or $0.36 per s...h, Chairman, Chief Executive Officer and President...
(Date:11/5/2009)..., PALO ALTO, Calif., Nov. 5 /PRNewswire-FirstCa... today announced financial results for the third q...nues for the third quarter of 2009 were $30.8 mill...ed September 30, 2008. XYREM® (sodium oxybate... 2009 were $25.0 million, compared to $14.2 millio...
Breaking Medicine Technology:Cardiac Science Appoints Healthcare Executive Ronald A. Andrews, Jr. to Board of Directors 2Cardiac Science Appoints Healthcare Executive Ronald A. Andrews, Jr. to Board of Directors 3Cardiac Science Appoints Healthcare Executive Ronald A. Andrews, Jr. to Board of Directors 4Cardiac Science Appoints Healthcare Executive Ronald A. Andrews, Jr. to Board of Directors 5InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 2InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 3InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 4InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 5InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 7InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 8InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 9InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 10InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 11InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 12InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 13Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 2Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 3Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 4Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 5Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 6Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 7Canada Grants PLC Systems First Patent for RenalGuard 28R 29 52762 1Canada Grants PLC Systems First Patent for RenalGuard 28R 29 52762 2Questcor and Child Neurology Foundation Announce Creation of Infantile Spasms Awareness Week 52759 1Questcor and Child Neurology Foundation Announce Creation of Infantile Spasms Awareness Week 52759 2Questcor and Child Neurology Foundation Announce Creation of Infantile Spasms Awareness Week 52759 3Questcor and Child Neurology Foundation Announce Creation of Infantile Spasms Awareness Week 52759 4Cryo Cell Announces Celle 28SM 29 Research and Development Collaboration with Cryopraxis Cryobiology Ltd 4782 1Cryo Cell Announces Celle 28SM 29 Research and Development Collaboration with Cryopraxis Cryobiology Ltd 4782 2Cryo Cell Announces Celle 28SM 29 Research and Development Collaboration with Cryopraxis Cryobiology Ltd 4782 3Cryo Cell Announces Celle 28SM 29 Research and Development Collaboration with Cryopraxis Cryobiology Ltd 4782 4Cryo Cell Announces Celle 28SM 29 Research and Development Collaboration with Cryopraxis Cryobiology Ltd 4782 5
...ay 2007 - CeNeS Pharmaceuticals plc,(LSE: CEN), th...,the publication of an independent study in the re... II NMDA antagonist, CNS 5161. CeNeS,is developing...,pain. The independent study builds on the work th...n the study reported in ,Synapse, Dr Anat Biegon ...
...S WIRE)--May 4, 2007 - New data from a,randomized,...OPAXONE(R) (glatiramer acetate injection) along wi...linium (Gd)-enhancing lesions,of the brain by 63 p...remitting multiple sclerosis (RRMS), as measured b...ose receiving,COPAXONE(R) alone. Additionally, the...
Other Medicine Technology:Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 2Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 2Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 4Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 5
...ortex® reusable or disposable laryngoscope bla...ing bronze fiber-optic bundles provide the durabil...., ,The laryngoscope blades are available in a fu... in all popular styles including Miller, Macintosh...
...ngo-Laryngoscope provides a new standard in diagno...n Fujinon engineering combines high resolution opt...90 degree field of view inside a very impressive 3...F offers a compact, lightweight control section an...
Fiber Optic Articulating Tip Laryngoscope Blades
Phillips American Profile Fiberoptic Laryngoscopes
Medicine Products: